Identifying potent inhibitors for Mycobacterium tuberculosis MabA (FabG1)

Area of Science:

• Biochemistry
• Microbiology
• Drug Discovery

Background:

• Drug-resistant Mycobacterium tuberculosis (Mtb) strains present a significant global health challenge.
• Mycolic acids are crucial for Mtb cell wall integrity and are synthesized via FAS-I and FAS-II systems.
• MabA, a key enzyme in the FAS-II pathway, is a validated target for novel anti-tubercular agents.

Purpose of the Study:

• To identify novel inhibitors of the MabA enzyme as potential therapeutic agents against drug-resistant tuberculosis.
• To explore a diverse chemical space by screening a large compound library against MabA.

Main Methods:

• High-throughput screening of 1,792,771 compounds from seven databases.
• Computational methods including molecular docking, all-atom molecular dynamics simulations, and MM/PBSA binding free energy calculations.
• Structure-based drug design principles were applied to analyze compound-enzyme interactions.

Main Results:

• Identification of 48 novel lead compounds with significant binding activity against MabA, categorized into five distinct chemical classes.
• 47 of the identified compounds showed superior binding free energy compared to the known MabA inhibitor (compound 29).
• The study validated MabA as a druggable target and provided a strong foundation for further optimization.

Conclusions:

• The findings represent a significant advancement in the rational design of novel therapeutics for combating mycobacterial infections.
• The identified lead compounds offer promising starting points for developing new drugs to overcome tuberculosis drug resistance.
• This research contributes to the urgent need for new strategies against the growing threat of drug-resistant tuberculosis.